Health economics is a fairly large field, and there are tradeoffs everywhere. Generally, you try to maximise quality-adjusted life years gained, which for rare diseases doesn't tend to win.

If you can give one person ten good years for a million in a rare disease, you can give ten people twenty good years in a less rare disease, so those tend to get more funding.